FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

An expert discusses the importance of timely biomarker testing and emerging challenges in treatment sequencing for metastatic ...

E! News sits down with the cast of ‘Freakier Friday’ including Lindsay Lohan and she revealed the hilarious way her ...

The evacuation order has cut off the coastal area of Al Mawasi, where thousands of Palestinians are living in tents, from the ...

Cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to ...

This precision medicine approach, driven by granular, real-world evidence, is critical for reshaping clinical guidelines and ...

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

Oumaima Chouay, who fled her home in Montreal nearly a decade ago to join ISIS in Syria, is the first person in Canada ...

Deshawn Clark, 26, faced a mandatory life prison term after an Indian River County jury in May convicted him of first-degree ...